Pranoprofen benefits dry eyes

Article

Topical pranoprofen 0.1% reduces the ocular signs and symptoms of dry eyes and decreases inflammatory markers of conjunctival epithelial cells.

Topical pranoprofen 0.1% reduces the ocular signs and symptoms of dry eyes and decreases inflammatory markers of conjunctival epithelial cells, according to a study in the latest journal of Cornea.

Dr X. Liu et al., Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China, randomized 60 patients with dry eye into two groups.

Group 1 was administered topical pranoprofen 0.1% plus topical sodium hyaluronate 0.1%, while group 2 received sodium hyaluronate without pranoprofen. The outcome measures included ocular surface disease index (OSDI), tear film break-up time (TBUT), Schirmer I test results, ocular surface staining (OSS) results and conjunctival HLA-DR expression.

Group 1 demonstrated a significantly lower OSDI, OSS, and HLA-DR-positive cells, compared to group 2. However, TBUT was significantly longer in group 1 than group 2. On day 30 of the follow-up OSS differences between the group decreased in significance, but there were continued differences in OSDI, TBUT and HLA-DR expression between group 1 and 2.

On postoperative days 15 and 30 OSDI, TBUT and HLA-DR expression in group 1 demonstrated significant improvement, compared with results achieved in group 2. There were no significant effects in either group in the Schirmer test I values at days 15 and 30.

The abstract for this study can be found here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.